We do appreciate the efforts led by the FAIR Initiative and hope to continue to partner with ACCELERATE to speed up the delivery of innovative therapies to children and adolescents.
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies